Boundless Bio, Inc.
Boundless Bio, Inc. (Nasdaq: BBIO) is a clinical-stage oncology company dedicated to developing novel therapeutics targeting extrachromosomal DNA (ecDNA) in cancer patients. The company's website is www.boundlessbio.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Boundless Bio, Inc. does
In the company’s own words
Boundless Bio, Inc. (Nasdaq: BBIO) is a clinical-stage oncology company dedicated to developing novel therapeutics targeting extrachromosomal DNA (ecDNA) in cancer patients. The company's website is www.boundlessbio.com.
The company focuses on addressing a significant unmet medical need in patients with oncogene amplified tumors, which represent approximately 25 percent of all cancer cases and affect an estimated 750,000 new patients annually across the United States, European Union, and Japan. Boundless Bio's proprietary Spyglass platform identifies targets essential for ecDNA functionality in cancer cells, enabling the discovery and development of ecDNA-directed therapeutic candidates (ecDTx) designed to disrupt the cellular machinery that enables ecDNA amplification and function.
The company's lead program, BBI-940, is a novel oral selective degrader targeting a previously undrugged kinesin involved in DNA segregation. BBI-940 entered first-in-human clinical testing in February 2026 through the KOMODO-1 trial, evaluating the drug in patients with estrogen receptor positive and HER2 negative breast cancer as well as triple-negative breast cancer with luminal androgen receptor subtype. The company previously investigated BBI-355, a checkpoint kinase 1 inhibitor, in the POTENTIATE trial but ceased enrollment in January 2026 to prioritize the BBI-940 program.
Boundless Bio was founded in 2018 by ARCH Venture Partners and leading academic researchers in ecDNA biology. The company's scientific advisory board includes internationally recognized experts in cancer genomics and drug discovery. The company's approach represents a differentiation from traditional precision oncology by targeting the underlying amplification biology rather than specific oncogene proteins, employing a synthetic lethality strategy designed to preferentially kill ecDNA-dependent cancer cells while sparing healthy cells.
The company retains global rights to all its programs and has discovered all ecDTx candidates internally. Beyond BBI-940, Boundless Bio has preclinically validated multiple additional targets and continues deploying its Spyglass platform to identify novel therapeutic opportunities and potential complementary assets for development or acquisition.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- LA JOLLA, CA
- Fiscal year end
- December
- CIK
- 1782303
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Boundless Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Boundless Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Boundless Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Boundless Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Boundless Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”